Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshio Ohno

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Journal of Cancer Research and Clinical Oncology|April 9, 2024
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in JapanYosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto, et al.
World Journal of Urology|February 18, 2020
Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohortTomohisa Matsunaga, Kazumasa Komura, Takeshi Hashimoto, et al.
BMC Cancer|February 28, 2021
Distinct effect of body mass index by sex as a prognostic factor in localized renal cell carcinoma treated with nephrectomy ~ data from a multi-institutional study in Japan ~Takeshi Tsutsumi, Kazumasa Komura, Takeshi Hashimoto, et al.
Anticancer Research|August 1, 2025
Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With ImmunotherapyKoichi Sugimoto, Takafumi Minami, Shingo Toyoda, et al.
Annals of Surgical Oncology|June 27, 2019
The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in JapanKazumasa Komura, Takeshi Hashimoto, Takuya Tsujino, et al.
Japanese Journal of Clinical Oncology|August 23, 2024
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapyShingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, et al.
International Journal of Clinical Oncology|September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumabKeiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Clinical and Translational Radiation Oncology|December 22, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Shogo Yamazaki, Kazumasa Komura, et al.
BJU International|September 13, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinomaTaizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Journal of Cancer Research and Clinical Oncology|April 9, 2024
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in JapanYosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto, et al.
World Journal of Urology|February 18, 2020
Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohortTomohisa Matsunaga, Kazumasa Komura, Takeshi Hashimoto, et al.
BMC Cancer|February 28, 2021
Distinct effect of body mass index by sex as a prognostic factor in localized renal cell carcinoma treated with nephrectomy ~ data from a multi-institutional study in Japan ~Takeshi Tsutsumi, Kazumasa Komura, Takeshi Hashimoto, et al.
Anticancer Research|August 1, 2025
Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With ImmunotherapyKoichi Sugimoto, Takafumi Minami, Shingo Toyoda, et al.
Annals of Surgical Oncology|June 27, 2019
The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in JapanKazumasa Komura, Takeshi Hashimoto, Takuya Tsujino, et al.
Japanese Journal of Clinical Oncology|August 23, 2024
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapyShingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, et al.
International Journal of Clinical Oncology|September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumabKeiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Clinical and Translational Radiation Oncology|December 22, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Shogo Yamazaki, Kazumasa Komura, et al.
BJU International|September 13, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinomaTaizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, et al.
Pageof 11